Compositions and methods for inhibiting gene expression of LPA
US10662427B2 · kind B2 · utility
5Cited by
6References
39Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2018 |
| Grant date | May 26, 2020 |
| Priority date | — |
| Expiry date | Mar 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3517
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.